hit a plateau on tirzepatide How to Break Weight Loss Navigating Weight Loss Plateaus: When

Retatrutide is currently in Phase 3 clinical trials for obesity and metabolic conditions, not cancer treatment

The eight-month pediatric study by Mericq and colleagues reported no side effects or toxicities across dose levels of 0.3, 1.0, and 3.0 mcg/kg/day a meaningful safety signal, though in a different population from adult performance users

Compared to tirzepatide, CagriSema offers strong appetite suppression with similar weight loss, adding another powerful option for obesity treatment

Patients who insist on gluteal injection because they believe it's 'easier' or 'less visible' consistently report higher rates of injection site complications within the first 12 weeks of treatment